Skip to main content
. Author manuscript; available in PMC: 2011 Jan 15.
Published in final edited form as: Cancer Res. 2010 Jul 7;70(14):5963–5973. doi: 10.1158/0008-5472.CAN-10-1028

Fig 3. Prevention of β-catenin stabilisation by CCT031374.

Fig 3

a. β-catenin abundance in Western blots of lysates from mouse L-cells treated for 6h with 7.5μM BIO and 20μM of the indicated hit compounds. b. Decreased abundance of β-catenin in immunostained mouse L-cells and in Western blots of lysates from mouse L-cells treated with indicated concentrations of CCT031374 and 7.5μM BIO for 8h. Decreases of relative β-catenin/β-actin ratios in the Western blot were normalised to BIO (100%) and control (0%). Bar: 30μm c. Structures of analogues of CCT031374. CCT031374 is compound (1). EN300-05350 [compound (11)] is a structurally unrelated control of similar lipophilicity, pKa and H-bonding. d. IC50 values from reporter cell assays and Western blots of lysates from mouse L-cell using CCT031374 and its analogues. Key: Asterisks - no effect at the maximum concentration used; +. Compound (8) was toxic to mouse L-cells at this concentration (30μM); §. assay not done.